Published in J Virol on May 01, 1995
The extracellular signal-regulated kinase pathway phosphorylates AML1, an acute myeloid leukemia gene product, and potentially regulates its transactivation ability. Mol Cell Biol (1996) 1.51
Transcriptional activation of a retrovirus enhancer by CBF (AML1) requires a second factor: evidence for cooperativity with c-Myb. J Virol (1996) 1.19
Importance of a c-Myb binding site for lymphomagenesis by the retrovirus SL3-3. J Virol (1997) 1.14
Second-site proviral enhancer alterations in lymphomas induced by enhancer mutants of SL3-3 murine leukemia virus: negative effect of nuclear factor 1 binding site. J Virol (1997) 1.07
Increased lymphomagenicity and restored disease specificity of AML1 site (core) mutant SL3-3 murine leukemia virus by a second-site enhancer variant evolved in vivo. J Virol (1997) 1.06
Cytoplasmic sequestration of the polyomavirus enhancer binding protein 2 (PEBP2)/core binding factor alpha (CBFalpha) subunit by the leukemia-related PEBP2/CBFbeta-SMMHC fusion protein inhibits PEBP2/CBF-mediated transactivation. Mol Cell Biol (1998) 1.06
B-Cell lymphoma induction by akv murine leukemia viruses harboring one or both copies of the tandem repeat in the U3 enhancer. J Virol (1998) 1.04
CBF, Myb, and Ets binding sites are important for activity of the core I element of the murine retrovirus SL3-3 in T lymphocytes. J Virol (1998) 0.99
Selection of reversions and suppressors of a mutation in the CBF binding site of a lymphomagenic retrovirus. J Virol (1999) 0.96
Functional characterization of ETV6 and ETV6/CBFA2 in the regulation of the MCSFR proximal promoter. Proc Natl Acad Sci U S A (1997) 0.95
ETS-core binding factor: a common composite motif in antigen receptor gene enhancers. Mol Cell Biol (1998) 0.95
An SL3-3 murine leukemia virus enhancer variant more pathogenic than the wild type obtained by assisted molecular evolution in vivo. J Virol (1997) 0.95
Type B leukemogenic virus has a T-cell-specific enhancer that binds AML-1. J Virol (2001) 0.94
Core-binding factor influences the disease specificity of Moloney murine leukemia virus. J Virol (1999) 0.93
The feline leukemia virus long terminal repeat contains a potent genetic determinant of T-cell lymphomagenicity. J Virol (1997) 0.90
RUNX1 and RUNX2 upregulate Galectin-3 expression in human pituitary tumors. Endocrine (2008) 0.90
Competitive binding of viral E2 protein and mammalian core-binding factor to transcriptional control sequences of human papillomavirus type 8 and bovine papillomavirus type 1. J Virol (1997) 0.83
ALY is a common coactivator of RUNX1 and c-Myb on the type B leukemogenic virus enhancer. J Virol (2007) 0.83
Suppressor mutations within the core binding factor (CBF/AML1) binding site of a T-cell lymphomagenic retrovirus. J Virol (1999) 0.82
Increased induction of osteopetrosis, but unaltered lymphomagenicity, by murine leukemia virus SL3-3 after mutation of a nuclear factor 1 site in the enhancer. J Virol (1999) 0.81
RUNX1 permits E4orf6-directed nuclear localization of the adenovirus E1B-55K protein and associates with centers of viral DNA and RNA synthesis. J Virol (2008) 0.80
Long terminal repeat regions from exogenous but not endogenous feline leukemia viruses transactivate cellular gene expression. J Virol (2000) 0.80
Core Binding Factor Acute Myeloid Leukemia: New Prognostic Categories and Therapeutic Opportunities. Semin Hematol (2015) 0.77
SARS coronavirus 3b accessory protein modulates transcriptional activity of RUNX1b. PLoS One (2012) 0.76
Aberrant epigenetic regulators control expansion of human CD34+ hematopoietic stem/progenitor cells. Front Genet (2013) 0.75
Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells. Mol Cell Biol (1982) 116.75
How eukaryotic transcriptional activators work. Nature (1988) 19.34
Multiple point mutations affecting the simian virus 40 enhancer. Science (1983) 13.69
Enhancer elements. Cell (1983) 10.41
Optimized use of the firefly luciferase assay as a reporter gene in mammalian cell lines. Biotechniques (1990) 5.02
t(8;21) breakpoints on chromosome 21 in acute myeloid leukemia are clustered within a limited region of a single gene, AML1. Proc Natl Acad Sci U S A (1991) 4.96
Determination of the leukaemogenicity of a murine retrovirus by sequences within the long terminal repeat. Nature (1984) 4.90
PEBP2/PEA2 represents a family of transcription factors homologous to the products of the Drosophila runt gene and the human AML1 gene. Proc Natl Acad Sci U S A (1993) 4.05
Six distinct nuclear factors interact with the 75-base-pair repeat of the Moloney murine leukemia virus enhancer. Mol Cell Biol (1987) 4.02
Fusion between transcription factor CBF beta/PEBP2 beta and a myosin heavy chain in acute myeloid leukemia. Science (1993) 3.88
Interaction of murine ets-1 with GGA-binding sites establishes the ETS domain as a new DNA-binding motif. Genes Dev (1992) 3.69
Molecular cloning and characterization of PEBP2 beta, the heterodimeric partner of a novel Drosophila runt-related DNA binding protein PEBP2 alpha. Virology (1993) 3.37
Identification of AML-1 and the (8;21) translocation protein (AML-1/ETO) as sequence-specific DNA-binding proteins: the runt homology domain is required for DNA binding and protein-protein interactions. Mol Cell Biol (1993) 3.17
Cloning and characterization of subunits of the T-cell receptor and murine leukemia virus enhancer core-binding factor. Mol Cell Biol (1993) 3.07
AML1, AML2, and AML3, the human members of the runt domain gene-family: cDNA structure, expression, and chromosomal localization. Genomics (1994) 3.02
The t(8;21) translocation in acute myeloid leukemia results in production of an AML1-MTG8 fusion transcript. EMBO J (1993) 3.00
Mutation of the core or adjacent LVb elements of the Moloney murine leukemia virus enhancer alters disease specificity. Genes Dev (1990) 2.75
Purification of a mouse nuclear factor that binds to both the A and B cores of the polyomavirus enhancer. J Virol (1990) 2.69
Isolation of PEBP2 alpha B cDNA representing the mouse homolog of human acute myeloid leukemia gene, AML1. Oncogene (1993) 2.67
The Runt domain identifies a new family of heteromeric transcriptional regulators. Trends Genet (1993) 2.65
Cell-type specific expression of a transfected immunoglobulin gene. Nature (1983) 2.56
Alignment of U3 region sequences of mammalian type C viruses: identification of highly conserved motifs and implications for enhancer design. J Virol (1990) 2.34
Differential protein binding in lymphocytes to a sequence in the enhancer of the mouse retrovirus SL3-3. Mol Cell Biol (1988) 2.27
PEBP2 alpha B/mouse AML1 consists of multiple isoforms that possess differential transactivation potentials. Mol Cell Biol (1994) 2.27
Generation of the AML1-EVI-1 fusion gene in the t(3;21)(q26;q22) causes blastic crisis in chronic myelocytic leukemia. EMBO J (1994) 2.12
Purification of core-binding factor, a protein that binds the conserved core site in murine leukemia virus enhancers. Mol Cell Biol (1992) 2.10
Identification of the SL3-3 virus enhancer core as a T-lymphoma cell-specific element. J Virol (1989) 2.07
The 3;21 translocation in myelodysplasia results in a fusion transcript between the AML1 gene and the gene for EAP, a highly conserved protein associated with the Epstein-Barr virus small RNA EBER 1. Proc Natl Acad Sci U S A (1993) 1.97
SL3-3 enhancer factor 1 transcriptional activators are required for tumor formation by SL3-3 murine leukemia virus. J Virol (1991) 1.92
Correlation of leukemogenic potential of murine retroviruses with transcriptional tissue preference of the viral long terminal repeats. J Virol (1987) 1.85
Binding of SL3-3 enhancer factor 1 transcriptional activators to viral and chromosomal enhancer sequences. J Virol (1991) 1.78
Sequence specificity of the core-binding factor. J Virol (1993) 1.63
Leukaemia/Drosophila homology. Nature (1992) 1.63
Indistinguishable nuclear factor binding to functional core sites of the T-cell receptor delta and murine leukemia virus enhancers. Mol Cell Biol (1992) 1.51
The murine myeloperoxidase promoter contains several functional elements, one of which binds a cell type-restricted transcription factor, myeloid nuclear factor 1 (MyNF1). Mol Cell Biol (1993) 1.48
Expression of the Runt domain-encoding PEBP2 alpha genes in T cells during thymic development. Mol Cell Biol (1995) 1.47
A phorbol ester response element within the human T-cell receptor beta-chain enhancer. Proc Natl Acad Sci U S A (1992) 1.44
Involvement of the AML1 gene in the t(3;21) in therapy-related leukemia and in chronic myeloid leukemia in blast crisis. Blood (1993) 1.44
Long terminal repeat enhancer core sequences in proviruses adjacent to c-myc in T-cell lymphomas induced by a murine retrovirus. J Virol (1995) 1.43
Relative importance of elements within the SL3-3 virus enhancer for T-cell specificity. J Virol (1990) 1.41
t(3;21)(q26;q22): a recurring chromosomal abnormality in therapy-related myelodysplastic syndrome and acute myeloid leukemia. Blood (1990) 1.31
Identification of a critical regulatory site in the human interleukin-3 promoter by in vivo footprinting. Blood (1994) 1.22
Two factors that bind to highly conserved sequences in mammalian type C retroviral enhancers. J Virol (1993) 1.11
The role of viral enhancer "core" motif-related sequences in regulating T cell receptor-gamma and -delta gene expression. J Immunol (1993) 1.08
Characterization of a protein that binds multiple sequences in mammalian type C retrovirus enhancers. J Virol (1993) 0.96
Purification of SEF1 proteins binding to transcriptional enhancer elements active in T lymphocytes. J Biol Chem (1993) 0.89
SEF1 binding is important for T cell specific enhancers of genes for T cell receptor-CD3 subunits. Nucleic Acids Res (1992) 0.84
Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat Genet (1999) 6.61
Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis. Proc Natl Acad Sci U S A (1996) 6.29
Determination of the leukaemogenicity of a murine retrovirus by sequences within the long terminal repeat. Nature (1984) 4.90
Insertional polymorphisms of full-length endogenous retroviruses in humans. Curr Biol (2001) 4.53
Cbfa2 is required for the formation of intra-aortic hematopoietic clusters. Development (1999) 4.21
Fracture of neck of the femur: changing incidence. Br Med J (Clin Res Ed) (1981) 4.18
Six distinct nuclear factors interact with the 75-base-pair repeat of the Moloney murine leukemia virus enhancer. Mol Cell Biol (1987) 4.02
The CBFbeta subunit is essential for CBFalpha2 (AML1) function in vivo. Cell (1996) 3.55
Nucleotide sequence of the Akv env gene. J Virol (1982) 3.53
Definitive hematopoietic stem cells first develop within the major arterial regions of the mouse embryo. EMBO J (2000) 3.10
Cloning and characterization of subunits of the T-cell receptor and murine leukemia virus enhancer core-binding factor. Mol Cell Biol (1993) 3.07
Embryonic lethality and impairment of haematopoiesis in mice heterozygous for an AML1-ETO fusion gene. Nat Genet (1997) 2.64
Many human endogenous retrovirus K (HERV-K) proviruses are unique to humans. Curr Biol (1999) 2.55
Trends in admissions for hip fracture in England and Wales, 1968-85. BMJ (1990) 2.35
Alignment of U3 region sequences of mammalian type C viruses: identification of highly conserved motifs and implications for enhancer design. J Virol (1990) 2.34
Tissue selectivity of murine leukemia virus infection is determined by long terminal repeat sequences. J Virol (1985) 2.29
Cooperative binding of Ets-1 and core binding factor to DNA. Mol Cell Biol (1994) 2.27
Purification of core-binding factor, a protein that binds the conserved core site in murine leukemia virus enhancers. Mol Cell Biol (1992) 2.10
Identification of the SL3-3 virus enhancer core as a T-lymphoma cell-specific element. J Virol (1989) 2.07
Correlation of leukemogenic potential of murine retroviruses with transcriptional tissue preference of the viral long terminal repeats. J Virol (1987) 1.85
Failure of embryonic hematopoiesis and lethal hemorrhages in mouse embryos heterozygous for a knocked-in leukemia gene CBFB-MYH11. Cell (1996) 1.84
Transactivation of the Moloney murine leukemia virus and T-cell receptor beta-chain enhancers by cbf and ets requires intact binding sites for both proteins. J Virol (1995) 1.80
The leukemia-associated AML1 (Runx1)--CBF beta complex functions as a DNA-induced molecular clamp. Nat Struct Biol (2001) 1.77
Sequence specificity of the core-binding factor. J Virol (1993) 1.63
Auto-inhibition of Ets-1 is counteracted by DNA binding cooperativity with core-binding factor alpha2. Mol Cell Biol (2000) 1.62
Auto-inhibition and partner proteins, core-binding factor beta (CBFbeta) and Ets-1, modulate DNA binding by CBFalpha2 (AML1). Mol Cell Biol (2000) 1.58
Rapid, high-yield production in plants of individualized idiotype vaccines for non-Hodgkin's lymphoma. Ann Oncol (2010) 1.55
Indistinguishable nuclear factor binding to functional core sites of the T-cell receptor delta and murine leukemia virus enhancers. Mol Cell Biol (1992) 1.51
Biotechnological advantages of laboratory-scale solid-state fermentation with fungi. Appl Microbiol Biotechnol (2004) 1.50
A phorbol ester response element within the human T-cell receptor beta-chain enhancer. Proc Natl Acad Sci U S A (1992) 1.44
Depletion of CD25(+) CD4(+) T cells and treatment with tyrosinase-related protein 2-transduced dendritic cells enhance the interferon alpha-induced, CD8(+) T-cell-dependent immune defense of B16 melanoma. Cancer Res (2001) 1.43
Long terminal repeat enhancer core sequences in proviruses adjacent to c-myc in T-cell lymphomas induced by a murine retrovirus. J Virol (1995) 1.43
Relative importance of elements within the SL3-3 virus enhancer for T-cell specificity. J Virol (1990) 1.41
Linking birthweight and birth registration data. Community Med (1980) 1.39
CBF beta-SMMHC, expressed in M4Eo AML, reduced CBF DNA-binding and inhibited the G1 to S cell cycle transition at the restriction point in myeloid and lymphoid cells. Oncogene (1997) 1.33
Molecular cloning of a highly leukemogenic, ecotropic retrovirus from an AKR mouse. J Virol (1982) 1.27
Localization of the leukemogenic determinants of SL3-3, an ecotropic, XC-positive murine leukemia virus of AKR mouse origin. J Virol (1983) 1.25
The leukemic protein core binding factor beta (CBFbeta)-smooth-muscle myosin heavy chain sequesters CBFalpha2 into cytoskeletal filaments and aggregates. Mol Cell Biol (1998) 1.24
Identification of a critical regulatory site in the human interleukin-3 promoter by in vivo footprinting. Blood (1994) 1.22
DNA binding properties of YB-1 and dbpA: binding to double-stranded, single-stranded, and abasic site containing DNAs. Nucleic Acids Res (1991) 1.19
Transcriptional activation of a retrovirus enhancer by CBF (AML1) requires a second factor: evidence for cooperativity with c-Myb. J Virol (1996) 1.19
Identification of a new murine runt domain-containing gene, Cbfa3, and localization of the human homolog, CBFA3, to chromosome 1p35-pter. Genomics (1995) 1.17
Differences in activities of murine retroviral long terminal repeats in cytotoxic T lymphocytes and T-lymphoma cells. J Virol (1989) 1.16
Importance of a c-Myb binding site for lymphomagenesis by the retrovirus SL3-3. J Virol (1997) 1.14
Prevalence of overweight and obesity and trends in body mass index in German pre-school children, 1982-1997. Int J Obes Relat Metab Disord (2002) 1.12
Two factors that bind to highly conserved sequences in mammalian type C retroviral enhancers. J Virol (1993) 1.11
Phrenic nerve conduction velocities in the young rat. J Physiol (1968) 1.10
R region sequences in the long terminal repeat of a murine retrovirus specifically increase expression of unspliced RNAs. J Virol (1999) 1.10
The role of viral enhancer "core" motif-related sequences in regulating T cell receptor-gamma and -delta gene expression. J Immunol (1993) 1.08
Notch signaling in mammalian hematopoietic stem cells. Leukemia (2011) 1.08
Retroviral insertional mutagenesis of a target allele in a heterozygous murine cell line. Proc Natl Acad Sci U S A (1985) 1.07
Retracted The leukemic core binding factor beta-smooth muscle myosin heavy chain (CBF beta-SMMHC) chimeric protein requires both CBF beta and myosin heavy chain domains for transformation of NIH 3T3 cells. Proc Natl Acad Sci U S A (1995) 1.07
Identification of a second human acetyl-CoA carboxylase gene. Biochem J (1996) 1.07
The secondary structure of the R region of a murine leukemia virus is important for stimulation of long terminal repeat-driven gene expression. J Virol (1998) 1.04
The Ig fold of the core binding factor alpha Runt domain is a member of a family of structurally and functionally related Ig-fold DNA-binding domains. Structure (1999) 1.04
Energetic and functional contribution of residues in the core binding factor beta (CBFbeta ) subunit to heterodimerization with CBFalpha. J Biol Chem (2000) 1.03
Biochemical and biophysical properties of the core-binding factor alpha2 (AML1) DNA-binding domain. J Biol Chem (1996) 1.01
Solution structure of core binding factor beta and map of the CBF alpha binding site. Nat Struct Biol (1999) 1.01
cis-acting elements in the U3 region of a simian immunodeficiency virus. J Virol (1990) 1.01
The personal telemedicine system. A new tool for the delivery of health care. J Telemed Telecare (1995) 1.00
Overexpression, purification, and biophysical characterization of the heterodimerization domain of the core-binding factor beta subunit. J Biol Chem (1998) 1.00
CBF, Myb, and Ets binding sites are important for activity of the core I element of the murine retrovirus SL3-3 in T lymphocytes. J Virol (1998) 0.99
Characterization of a protein that binds multiple sequences in mammalian type C retrovirus enhancers. J Virol (1993) 0.96
Potential roles for RUNX1 and its orthologs in determining hematopoietic cell fate. Semin Cell Dev Biol (2000) 0.96
Selection of reversions and suppressors of a mutation in the CBF binding site of a lymphomagenic retrovirus. J Virol (1999) 0.96
ETS-core binding factor: a common composite motif in antigen receptor gene enhancers. Mol Cell Biol (1998) 0.95
An international trial of quantitative PCR for monitoring Legionella in artificial water systems. J Appl Microbiol (2011) 0.94
Core-binding factor influences the disease specificity of Moloney murine leukemia virus. J Virol (1999) 0.93
[Treatment of pilonidal sinus with excision and primary suture using a local, resorbable antibiotic carrier. Results of a prospective randomized study]. Chirurg (1992) 0.93
Balb/c T cells have the potential to recognize the TEPC 15 prototype antibody and its somatic variants. J Exp Med (1981) 0.92
Biophysical characterization of interactions between the core binding factor alpha and beta subunits and DNA. FEBS Lett (2000) 0.92
The effect of chlorpropamide on water balance in pitressin-treated Brattleboro rats. Br J Pharmacol (1974) 0.91
Transcriptional initiation and postinitiation effects of murine leukemia virus long terminal repeat R-region sequences. J Virol (1991) 0.90
The feline leukemia virus long terminal repeat contains a potent genetic determinant of T-cell lymphomagenicity. J Virol (1997) 0.90
Detection of Helicobacter pylori in biofilms by real-time PCR. Int J Hyg Environ Health (2010) 0.89
Retracted Overexpression of core-binding factor alpha (CBF alpha) reverses cellular transformation by the CBF beta-smooth muscle myosin heavy chain chimeric oncoprotein. Mol Cell Biol (1995) 0.88
The role of platelet aggregation in the development of endotoxin shock. Br J Surg (1969) 0.87
Core-binding factor beta (CBFbeta), but not CBFbeta-smooth muscle myosin heavy chain, rescues definitive hematopoiesis in CBFbeta-deficient embryonic stem cells. Blood (2001) 0.87
Construction of a replication-competent murine retrovirus vector expressing the human immunodeficiency virus type 1 tat transactivator protein. J Virol (1991) 0.86
A HERV-K provirus in chimpanzees, bonobos and gorillas, but not humans. Curr Biol (2001) 0.86
Identification, cloning, expression, and characterization of the extracellular acarbose-modifying glycosyltransferase, AcbD, from Actinoplanes sp. strain SE50. J Bacteriol (2001) 0.85
Circulating clonal CLA(+) and CD4(+) T cells in Sezary syndrome express the skin-homing chemokine receptors CCR4 and CCR10 as well as the lymph node-homing chemokine receptor CCR7. Br J Dermatol (2005) 0.85
Thiazolo[4,5-d]pyrimidines. Part II. Synthesis and anti-human cytomegalovirus activity in vitro of certain acyclonucleosides and acyclonucleotides derived from the guanine analogue 5-aminothiazolo[4,5-d]pyrimidine-2,7(3H,6H)-dione. Antivir Chem Chemother (1998) 0.85
CFU-S(11) activity does not localize solely with the aorta in the aorta-gonad-mesonephros region. Blood (2000) 0.85
Synthesis and antiviral activity of certain guanosine analogues in the thiazolo[4,5-d]pyrimidine ring system. J Med Chem (1991) 0.83
Differential activity patterns in the masseter muscle under simulated clenching and grinding forces. J Oral Rehabil (2005) 0.83
Cardiovascular effects of a novel potent and highly selective azaindole-based inhibitor of Rho-kinase. Br J Pharmacol (2007) 0.82
Suppressor mutations within the core binding factor (CBF/AML1) binding site of a T-cell lymphomagenic retrovirus. J Virol (1999) 0.82
Primary amines inhibit the triggering of B lymphocytes to antibody synthesis. J Immunol (1983) 0.82
[Correlation of lymph node size and metastatic involvement of lymph nodes in bronchial cancer]. Langenbecks Arch Chir (1990) 0.82
N-Methylformycins. Reactivity with adenosine deaminase, incorporation into intracellular nucleotides of human erythrocytes and L 1210 cells and cytotoxicity to L 1210 cells. Biochem Pharmacol (1979) 0.81